

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-072024-000985

Date:

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Epcoritamab
- Loncastuximab tesirine
- Glofitamab
- Any other SACT
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatments

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel)

- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatment

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

Response

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

13

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Based on the data provided from Chemocare there were 25 patients diagnosed with DLBCL that received Treatment at Dudley Group Foundation Trust between April 2024 and September 2024.

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)

Axicabtagene ciloleucel (Yescarta)

Tisagenlecleucel

Epcoritamab

Loncastuximab tesirine

Glofitamab

Any other SACT

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

The data in Chemocare shows the below number of patients diagnosed with DLBCL that had treatment mentioned above between April 2024 and September 2024:

POLA-R-CHP	2
R-CHOP 21 (1ST)	5
R-MINI-CHOP 1ST	2

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta)

Tisagenlecleucel

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Any other treatments

The data in Chemocare shows the below number of patients diagnosed with DLBCL that had treatment mentioned above between April 2024 and September 2024:

POLA-R-CHP C2+	1
R-CHOP 21 (2ND+)	4
R-MINI-CHOP 2ND+	4

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

CAR-T Therapy (E.g. Axicabtagene ciloleucel):

0

Stem cell transplant or bone marrow transplant (autologous or allogeneic) 0

Any other treatment

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling? **No trials available**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team
The Dudley Group NHS Foundation Trust**